Tal Marom1, Alai Tan2, Gregg S Wilkinson2, Karen S Pierson2, Jean L Freeman2, Tasnee Chonmaitree3. 1. Division of Pediatric Infectious Diseases, Department of Pediatrics, The University of Texas Medical Branch, Galveston. 2. Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston. 3. Division of Pediatric Infectious Diseases, Department of Pediatrics, The University of Texas Medical Branch, Galveston3Department of Pathology, The University of Texas Medical Branch, Galveston.
Abstract
IMPORTANCE: Otitis media (OM) is a leading cause of pediatric health care visits and the most frequent reason children consume antibiotics or undergo surgery. During recent years, several interventions have been introduced aiming to decrease OM burden. OBJECTIVE: To study the trend in OM-related health care use in the United States during the pneumococcal conjugate vaccine (PCV) era (2001-2011). DESIGN, SETTING, AND PARTICIPANTS: An analysis of an insurance claims database of a large, nationwide managed health care plan was conducted. Enrolled children aged 6 years or younger with OM visits were identified. MAIN OUTCOMES AND MEASURES: Annual OM visit rates, OM-related complications, and surgical interventions were analyzed. RESULTS: Overall, 7.82 million unique children (5.51 million child-years) contributed 6.21 million primary OM visits; 52% were boys and 48% were younger than 2 years. There was a downward trend in OM visit rates from 2004 to 2011, with a significant drop that coincided with the advent of the 13-valent vaccine (PCV-13) in 2010. The observed OM visit rates in 2010 (1.00/child-year) and 2011 (0.81/child-year) were lower than the projected rates based on the 2005-2009 trend had there been no intervention (P < .001). Recurrent OM (≥3 OM visits within 6-month look-back) rates decreased at 0.003/child-year (95% CI, 0.002-0.004/child-year) in 2001-2009 and at 0.018/child-year (95% CI, 0.008-0.028/child-year) in 2010-2011. In the PCV-13 premarket years, there was a stable rate ratio (RR) between OM visit rates in children younger than 2 years and in those aged 2 to 6 years (RR, 1.38; 95% CI, 1.38-1.39); the RR decreased significantly (P < .001) during the transition year 2010 (RR 1.32; 95% CI, 1.31-1.33) and the postmarket year 2011 (RR 1.01; 95% CI, 1.00-1.02). Tympanic membrane perforation/otorrhea rates gradually increased (from 3721 per 100,000 OM child-years in 2001 to 4542 per 100,000 OM child-years in 2011; P < .001); the increase was significant only in the older children group. Mastoiditis rates substantially decreased (from 61 per 100,000 child-years in 2008 to 37 per 100,000 child-years in 2011; P < .001). Ventilating tube insertion rate decreased by 19% from 2010 to 2011 (P = .03). CONCLUSIONS AND RELEVANCE: There was an overall downward trend in OM-related health care use from 2001 to 2011. The significant reduction in OM visit rates in 2010-2011 in children younger than 2 years coincided with the advent of PCV-13. Although tympanic membrane perforation/otorrhea rates steadily increased during that period, mastoiditis and ventilating tube insertion rates decreased in the last years of the study.
IMPORTANCE: Otitis media (OM) is a leading cause of pediatric health care visits and the most frequent reason children consume antibiotics or undergo surgery. During recent years, several interventions have been introduced aiming to decrease OM burden. OBJECTIVE: To study the trend in OM-related health care use in the United States during the pneumococcal conjugate vaccine (PCV) era (2001-2011). DESIGN, SETTING, AND PARTICIPANTS: An analysis of an insurance claims database of a large, nationwide managed health care plan was conducted. Enrolled children aged 6 years or younger with OM visits were identified. MAIN OUTCOMES AND MEASURES: Annual OM visit rates, OM-related complications, and surgical interventions were analyzed. RESULTS: Overall, 7.82 million unique children (5.51 million child-years) contributed 6.21 million primary OM visits; 52% were boys and 48% were younger than 2 years. There was a downward trend in OM visit rates from 2004 to 2011, with a significant drop that coincided with the advent of the 13-valent vaccine (PCV-13) in 2010. The observed OM visit rates in 2010 (1.00/child-year) and 2011 (0.81/child-year) were lower than the projected rates based on the 2005-2009 trend had there been no intervention (P < .001). Recurrent OM (≥3 OM visits within 6-month look-back) rates decreased at 0.003/child-year (95% CI, 0.002-0.004/child-year) in 2001-2009 and at 0.018/child-year (95% CI, 0.008-0.028/child-year) in 2010-2011. In the PCV-13 premarket years, there was a stable rate ratio (RR) between OM visit rates in children younger than 2 years and in those aged 2 to 6 years (RR, 1.38; 95% CI, 1.38-1.39); the RR decreased significantly (P < .001) during the transition year 2010 (RR 1.32; 95% CI, 1.31-1.33) and the postmarket year 2011 (RR 1.01; 95% CI, 1.00-1.02). Tympanic membrane perforation/otorrhea rates gradually increased (from 3721 per 100,000 OM child-years in 2001 to 4542 per 100,000 OM child-years in 2011; P < .001); the increase was significant only in the older children group. Mastoiditis rates substantially decreased (from 61 per 100,000 child-years in 2008 to 37 per 100,000 child-years in 2011; P < .001). Ventilating tube insertion rate decreased by 19% from 2010 to 2011 (P = .03). CONCLUSIONS AND RELEVANCE: There was an overall downward trend in OM-related health care use from 2001 to 2011. The significant reduction in OM visit rates in 2010-2011 in children younger than 2 years coincided with the advent of PCV-13. Although tympanic membrane perforation/otorrhea rates steadily increased during that period, mastoiditis and ventilating tube insertion rates decreased in the last years of the study.
Authors: Terho Heikkinen; Stan L Block; Seth L Toback; Xionghua Wu; Christopher S Ambrose Journal: Pediatr Infect Dis J Date: 2013-06 Impact factor: 2.129
Authors: J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä Journal: N Engl J Med Date: 2001-02-08 Impact factor: 91.245
Authors: Alejandro Hoberman; David P Greenberg; Jack L Paradise; Howard E Rockette; Judith R Lave; Diana H Kearney; D Kathleen Colborn; Marcia Kurs-Lasky; Mary Ann Haralam; Carol J Byers; Lisa M Zoffel; Irene A Fabian; Beverly S Bernard; Jill D Kerr Journal: JAMA Date: 2003-09-24 Impact factor: 56.272
Authors: Richard M Rosenfeld; Larry Culpepper; Karen J Doyle; Kenneth M Grundfast; Alejandro Hoberman; Margaret A Kenna; Allan S Lieberthal; Martin Mahoney; Richard A Wahl; Charles R Woods; Barbara Yawn Journal: Otolaryngol Head Neck Surg Date: 2004-05 Impact factor: 3.497
Authors: Bruce Fireman; Steven B Black; Henry R Shinefield; Janelle Lee; Edwin Lewis; Paula Ray Journal: Pediatr Infect Dis J Date: 2003-01 Impact factor: 2.129
Authors: P Pellegrino; C Carnovale; V Perrone; D Salvati; M Gentili; T Brusadelli; S Antoniazzi; M Pozzi; S Radice; E Clementi Journal: Eur J Clin Microbiol Infect Dis Date: 2014-04-23 Impact factor: 3.267
Authors: Guillermo L Monroy; Paritosh Pande; Ryan M Nolan; Ryan L Shelton; Ryan G Porter; Michael A Novak; Darold R Spillman; Eric J Chaney; Daniel T McCormick; Stephen A Boppart Journal: J Biomed Opt Date: 2017-12 Impact factor: 3.170
Authors: Mirabelle Sajisevi; Kristine Schulz; Derek D Cyr; Daniel Wojdyla; Richard M Rosenfeld; Debara Tucci; David L Witsell Journal: Otolaryngol Head Neck Surg Date: 2016-10-03 Impact factor: 3.497
Authors: Daniel J Adams; Apryl Susi; Christine R Erdie-Lalena; Gregory Gorman; Elizabeth Hisle-Gorman; Michael Rajnik; Marilisa Elrod; Cade M Nylund Journal: J Autism Dev Disord Date: 2016-05